Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia

References

• Pushpa-Rajah JA, McLoughlin BC, Gillies D, et al. Cannabis and schizophrenia. Schizophr Bull. 2015;41:336–337.
   PubMed Web of Science ®Google Scholar
• Hamilton I. Cannabis, psychosis and schizophrenia: unraveling a complex interaction. Addiction. 2017;112:1653–1657.
   PubMed Web of Science ®Google Scholar
• Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;330:1483–1486.
   Web of Science ®Google Scholar
• Gage SH, Jones HJ, Burgess S, et al. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 2016;47:1–10.
   PubMed Web of Science ®Google Scholar
• Foti DJ, Kotov R, Guey LT, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167:987–993.
   PubMed Web of Science ®Google Scholar
• Helle S, Ringen PA, Melle I, et al. Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119). Schizophr Res. 2016;170:217–221.
   PubMed Web of Science ®Google Scholar
• Rohleder C, Muller JK, Lange B, et al. Cannabidiol as a potential new type of an antipsychotic: a critical review of the evidence. Front Pharmacol. 2016;7:422.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94.
   PubMed Web of Science ®Google Scholar
• McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Ajp. 2018;175:225–231.
   Google Scholar
• D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57:594–608.
   PubMed Web of Science ®Google Scholar
• Morrison PD, Stone JM. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol Clin Exp. 2011;26:77–80.
   PubMed Web of Science ®Google Scholar
• Englund A, Freeman T, Murray R, et al. Can we make cannabis safer? Lancet Psychiatry. 2017;4:643–648.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacol. 2010;35:764–774.
   PubMed Web of Science ®Google Scholar
• Sami MS, Bhattacharyya S. Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. J Psychopharmacol. 2018;32:825–849.
   PubMed Web of Science ®Google Scholar
• Park YC, Yang S-Y, Chong M-Y, et al. Differences in high dose antipsychotic prescription in patients with schizophrenia in Asian countries/areas: findings from the REAP-AP study. Psychiatry Investig. 2018;15:1007–1008.
   PubMed Web of Science ®Google Scholar
• Park YC, Lee MS, Si TM, et al. Psychotropic drug-prescribing correlates of disorganized speech in Asians with schizophrenia: the REAP-AP study. Saudi Pharm J. 2019;27:246–253.
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
   Web of Science ®Google Scholar
• Inada T. DIEPSS: A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale. Tokyo: Seiwa Shoten Publishers, Inc.; 2019.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Diss. 1987;40:373–383.
   PubMedGoogle Scholar
• World Health Organization. Anatomical Therapeutic Chemical (ATC) classification system. [cited 2019 Jun 19] Available from: https://www.whocc.no/atc/structure_and_principles/.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorder, 5th ed. Washington, DC: American Psychiatric Press; 2015.
   Google Scholar
• Manrique-Garcia E, de Leon AP, Dalman C, et al. Cannabis, psychosis, and mortality: a cohort study of 50,373 Swedish men. Am J Psychiatry. 2016;173:790–798.
   PubMed Web of Science ®Google Scholar
• Skosnik PD, Krishnan GP, Aydt EE, et al. Psychophysiological evidence of altered neural synchronization in cannabis use: Relationship to schizotyphy. Am J Psychiatry. 2006;163:1798–1805.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kane JM, Kissling W, et al. Clinical implications of brief psychiatric rating scale score. Br J Psychiatry. 2005;187:366–371.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jung HY, Kang UK, et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale: a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17:1354–1359.
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” treatment and prevention. Past, present, and future. Schizophr Res. 2010;122:1–23.
   PubMed Web of Science ®Google Scholar
• Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69:440–447.
   PubMed Web of Science ®Google Scholar
• Sim K, Su A, Leong IY, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (Research on East Asian Psychotropic Prescriptions) study. Pharmacopsychiatry. 2004;37:175–179.
   PubMed Web of Science ®Google Scholar
• Tihonen J, Mittendorfer-Rutz E, Tornianen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepine in patients with schizophrenia: an observational follow-up study. Am J Psychiatry. 2016;173:600–606.
   PubMed Web of Science ®Google Scholar
• Hermos JA, Young MM, Lawler EV, et al. Long-term, high-dose benzodiazepine prescriptions in veteran patients with PTSD: Influence of preexisting alcoholism and drug-abuse diagnoses. J Traum Stress. 2007;20:909–914.
   PubMed Web of Science ®Google Scholar
• Cushman P, Benzer D. Benzodiazepines and drug abuse: clinical observations in chemically dependent persons before and during abstinence. Drug Alcohol Depend. 1980;6:365–371.
   PubMed Web of Science ®Google Scholar
• Ternavasio-de la Vega HG, Castaño-Romero F, Ragozzino S, et al. The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia. Epidemiol Infect. 2018;146:2122–2130.
   PubMed Web of Science ®Google Scholar
• Hodgins S, Klein S. New clinically relevant findings about violence by people with schizophrenia. Can J Psychiatry. 2017;62:86–93.
   PubMed Web of Science ®Google Scholar
• Koen L, Kinnear CJ, Corfield VA, et al. Violence in male patients with schizophrenia: risk markers in a South African population. Aust N Z J Psychiatry. 2004;38:254–259.
   PubMed Web of Science ®Google Scholar
• Soyka M. Neurobiology of aggression and violence in schizophrenia. Schizophr Bull. 2011;37:913–920.
   PubMed Web of Science ®Google Scholar
• Welch KA, Moorhead TW, McIntosh AM, et al. Tensor-based morphometry of cannabis use on brain structure in individuals at elevated genetic risk of schizophrenia. Psychol Med. 2013;43:2087–2096.
   PubMed Web of Science ®Google Scholar
• Rais M, van Haren NE, Cahn W, et al. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol. 2010;20:855–865.
   PubMed Web of Science ®Google Scholar
• Szeszko PR, Robinson DG, Sevy S, et al. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry. 2007;190:230–236.
   PubMed Web of Science ®Google Scholar
• Haney M, Evins AE. Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology. 2016;41:393–401.
   PubMed Web of Science ®Google Scholar
• Ibarra-Lecue I, Mollinedo-Gajate I, Meana JJ, et al. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway. Neuropsychopharmacol. 2018;43:2028–2035.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Shimodera S, Nishida A, et al. Psychotic-like experiences are associated with violent behavior in adolescents. Schizophr Res. 2011;126:245–251.
   PubMed Web of Science ®Google Scholar
• Manrique-Garcia E, Zammit S, Dalman C, et al. Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med. 2014;44:1–9.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry. 2016;3:215–225.
   PubMed Web of Science ®Google Scholar
• Park S-C, Choi MY, Park E, et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 2018;16:361–375.
   PubMed Web of Science ®Google Scholar
• Fond G, Boyer L, Favez M, et al. Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. Psychopharmacology. 2016;233:571–578.
   PubMed Web of Science ®Google Scholar
• Mallet J, Ramoz N, Le Strat Y, et al. Heavy cannabis use prior psychosis in schizophrenia: Clinical, cognitive and neurological evidences for a new endophenotype? Eur Arch Psychiatry Clin Neurosci. 2017;267:629–638.
   PubMed Web of Science ®Google Scholar